NGM 株式概要
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. 詳細
NGM Biopharmaceuticals, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$1.54 |
| 52週高値 | US$4.69 |
| 52週安値 | US$0.60 |
| ベータ | 1.27 |
| 11ヶ月の変化 | 1.32% |
| 3ヶ月変化 | 14.93% |
| 1年変化 | -59.79% |
| 33年間の変化 | -93.94% |
| 5年間の変化 | -90.41% |
| IPOからの変化 | -89.52% |
最新ニュース
Recent updates
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You
Dec 19
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
Oct 05Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates
Aug 09Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky
Jun 27NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't
Apr 17We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully
Dec 20NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails
Oct 17NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President
Jun 30NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022
Jun 21Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jun 15Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week
May 09NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad
Apr 26Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Feb 21We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely
Nov 08Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jul 09NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 06株主還元
| NGM | US Pharmaceuticals | US 市場 | |
|---|---|---|---|
| 7D | -3.1% | -1.4% | 0.3% |
| 1Y | -59.8% | 10.8% | 31.1% |
業界別リターン: NGM過去 1 年間で10.8 % の収益を上げたUS Pharmaceuticals業界を下回りました。
リターン対市場: NGMは、過去 1 年間で31.1 % のリターンを上げたUS市場を下回りました。
価格変動
| NGM volatility | |
|---|---|
| NGM Average Weekly Movement | 10.3% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: NGMの株価は過去 3 か月間にわたって変動しています。
時間の経過による変動: NGMの 週次ボラティリティ ( 10% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2007 | 138 | David Woodhouse | www.ngmbio.com |
NGM Biopharmaceuticals, Inc. 基礎のまとめ
| NGM 基礎統計学 | |
|---|---|
| 時価総額 | US$128.53m |
| 収益（TTM） | -US$142.37m |
| 売上高(TTM) | US$4.42m |
29.1x
P/Sレシオ-0.9x
PER（株価収益率NGM は割高か？
公正価値と評価分析を参照収益と収入
| NGM 損益計算書（TTM） | |
|---|---|
| 収益 | US$4.42m |
| 売上原価 | US$114.23m |
| 売上総利益 | -US$109.81m |
| その他の費用 | US$32.56m |
| 収益 | -US$142.37m |
直近の収益報告
Dec 31, 2023
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.71 |
| グロス・マージン | -2,486.12% |
| 純利益率 | -3,223.34% |
| 有利子負債／自己資本比率 | 0% |
NGM の長期的なパフォーマンスは？
過去の実績と比較を見る